Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Chemotherapy Induced Neutropenia Global Market 2016 Examination and Forecast to 2021

Thursday, October 13, 2016 21:40
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.


Get Sample Report @


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia

- The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects

- The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Buy 1-User PDF @


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Chemotherapy Induced Neutropenia Overview 10

Therapeutics Development 11

Pipeline Products for Chemotherapy Induced Neutropenia – Overview 11

Pipeline Products for Chemotherapy Induced Neutropenia – Comparative Analysis 12

Chemotherapy Induced Neutropenia – Therapeutics under Development by Companies 13

Chemotherapy Induced Neutropenia – Therapeutics under Investigation by Universities/Institutes 16

Chemotherapy Induced Neutropenia – Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Chemotherapy Induced Neutropenia – Products under Development by Companies 21

Chemotherapy Induced Neutropenia – Products under Investigation by Universities/Institutes 23

Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development 24

Apotex Inc. 24

Biocon Limited 25

Biogenomics Limited 26

Bolder Biotechnology, Inc. 27

Cellerant Therapeutics, Inc. 28

Chong Kun Dang Pharmaceutical Corp. 29

Cinfa Biotech S.L. 30

Dr. Reddy’s Laboratories Limited 31

Gene Techno Science Co., Ltd. 32

Generon (Shanghai) Corporation Ltd. 33

Genexine, Inc. 34

Hanmi Pharmaceuticals, Co. Ltd. 35

Myelo Therapeutics GmbH 36

Octapharma AG 37

Pfenex Inc. 38

Pfizer Inc. 39

Reliance Life Sciences Pvt. Ltd. 40

Richter Gedeon Nyrt. 41

Sandoz International GmbH 42


Access Report @


Reach Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           


Follow Us:




Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.